Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-11-24T13:39:38.037Z Has data issue: false hasContentIssue false
  • English
  • Français

Letter to the Editor

Published online by Cambridge University Press:  21 January 2005

Obed C. Onuzo
Obed C. Onuzo
Affiliation:
Department of Paediatric Cardiology, University Hospital of Wales, Cardiff, UK. E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Letters to the Editor
Information
Cardiology in the Young , Volume 14 , Issue 4 , August 2004 , pp. 466 - 467
Copyright
© 2004 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Tulloh R, Marsh M, Blackburn M, Casey F, Lenny W, Weller P, Keeton BR. Recommendations for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease. Cardiology in the Young 2003; 13: 420–423.Google Scholar
Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH, Connor EM, Sondheimer HM for the Cardiac Synagis Study Group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with haemodynamically significant congenital heart disease. J Pediatr 2003; 143: 532–540.Google Scholar